PhRMA Renews Legal Challenge To 340B Orphan Drug Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
HRSA issued an “interpretive” rule pertaining to discounts on orphan drugs in 340B after a federal judge invalidated the same policy as a “legislative” rule. Now, the pharma trade group asks the court to reject the policy in its “interpretive” form.